ABVCABVC BIOPHARMA, INC.

Nasdaq abvcpharma.com


$ 1.45 $ -0.17 (-10.69 %)    

Friday, 26-Apr-2024 15:58:03 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 1.42
$ 1.44
$ 0.00 x 0
$ 0.00 x 0
$ 1.43 - $ 1.56
$ 0.67 - $ 9.60
2,056,011
na
15M
$ 0.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-13-2024 12-31-2023 10-K
2 08-14-2023 06-30-2023 10-Q
3 05-15-2023 03-31-2023 10-Q
4 03-31-2023 12-31-2022 10-K
5 11-14-2022 09-30-2022 10-Q
6 08-15-2022 06-30-2022 10-Q
7 05-16-2022 03-31-2022 10-Q
8 03-31-2022 12-31-2021 10-K
9 11-15-2021 09-30-2021 10-Q
10 08-11-2021 06-30-2021 10-Q
11 05-10-2021 03-31-2021 10-Q
12 03-16-2021 12-31-2020 10-K
13 11-17-2020 09-30-2020 10-Q
14 08-14-2020 06-30-2020 10-Q
15 06-30-2020 03-31-2020 10-Q
16 05-15-2020 12-31-2019 10-K
17 11-18-2019 09-30-2019 10-Q
18 08-09-2019 06-30-2019 10-Q
19 05-28-2019 03-31-2019 10-Q
20 04-15-2019 12-31-2018 10-K
21 11-14-2018 09-30-2018 10-Q
22 08-20-2018 06-30-2018 10-Q
23 05-15-2018 03-31-2018 10-Q
24 01-16-2018 09-30-2017 10-K
25 08-21-2017 06-30-2017 10-Q
26 05-22-2017 03-31-2017 10-Q
27 02-21-2017 12-31-2016 10-Q
28 01-12-2017 09-30-2016 10-K
29 08-15-2016 06-30-2016 10-Q
30 05-16-2016 03-31-2016 10-Q
31 02-23-2016 12-31-2015 10-Q
32 11-27-2015 09-30-2015 10-K
33 08-19-2015 06-30-2015 10-Q
34 05-15-2015 03-31-2015 10-Q
35 04-17-2015 12-31-2013 10-Q
36 04-17-2015 03-31-2014 10-Q
37 04-17-2015 06-30-2014 10-Q
38 04-17-2015 09-30-2014 10-K
39 04-17-2015 12-31-2014 10-Q
40 04-16-2015 12-31-2012 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aibtl-biopharma-inc-acquired-tt-life-company-valued-at-833m-with-166m-aibtl-shares-at-5-per-share

ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solut...

 abvc-biopharma-executes-a-global-licensing-definitive-agreement-for-the-treatment-of-nsclc-expecting-aggregate-income-of-1375m-and-royalties-of-up-to-1250m

ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solut...

Core News & Articles
Market-Moving News for April 10th
04/10/2024 12:39:39

ADIL: 108% | Adial Pharmaceuticals shares are trading higher after the company announced the publication of a peer-reviewed art...

 abvc-biopharma-executes-a-global-licensing-term-sheet-for-oncologyhematology-products-expecting-licensing-income-of-55m-and-royalties-of-up-to-50m

 ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solu...

 why-abvc-biopharma-stock-is-up-today

ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus lic...

 abvc-biopharma-provides-fiscal-year-2024-q1-business-update

ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a biotechnology company specializing in botanically based solutions tha...

 abvcs-new-horizon-for-oncology-and-hematology-aims-at-cancer-market

 ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solu...

 why-mobileye-global-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION